Trade Zentalis Pharmaceuticals - ZNTL CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.04 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.023429% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.001207% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5.00% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 1.34 |
| Open | 1.41 |
| 1-Year Change | -89.08% |
| Day's Range | 1.35 - 1.45 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Apr 22, 2025 | 1.45 | 0.11 | 8.21% | 1.34 | 1.45 | 1.34 |
| Apr 21, 2025 | 1.34 | 0.09 | 7.20% | 1.25 | 1.38 | 1.25 |
| Apr 17, 2025 | 1.27 | 0.05 | 4.10% | 1.22 | 1.31 | 1.21 |
| Apr 16, 2025 | 1.24 | 0.04 | 3.33% | 1.20 | 1.26 | 1.18 |
| Apr 15, 2025 | 1.26 | 0.08 | 6.78% | 1.18 | 1.29 | 1.18 |
| Apr 14, 2025 | 1.20 | -0.03 | -2.44% | 1.23 | 1.24 | 1.16 |
| Apr 11, 2025 | 1.22 | 0.12 | 10.91% | 1.10 | 1.22 | 1.07 |
| Apr 10, 2025 | 1.12 | -0.02 | -1.75% | 1.14 | 1.14 | 1.03 |
| Apr 9, 2025 | 1.14 | 0.12 | 11.76% | 1.02 | 1.22 | 0.99 |
| Apr 8, 2025 | 1.01 | -0.16 | -13.68% | 1.17 | 1.21 | 1.00 |
| Apr 7, 2025 | 1.10 | 0.01 | 0.92% | 1.09 | 1.18 | 1.06 |
| Apr 4, 2025 | 1.14 | -0.09 | -7.32% | 1.23 | 1.27 | 1.10 |
| Apr 3, 2025 | 1.26 | 0.02 | 1.61% | 1.24 | 1.27 | 1.19 |
| Apr 2, 2025 | 1.33 | 0.01 | 0.76% | 1.32 | 1.39 | 1.31 |
| Apr 1, 2025 | 1.36 | -0.19 | -12.26% | 1.55 | 1.55 | 1.34 |
| Mar 31, 2025 | 1.56 | -0.15 | -8.77% | 1.71 | 1.71 | 1.56 |
| Mar 28, 2025 | 1.78 | 0.08 | 4.71% | 1.70 | 1.79 | 1.66 |
| Mar 27, 2025 | 1.76 | -0.07 | -3.83% | 1.83 | 1.99 | 1.72 |
| Mar 26, 2025 | 1.73 | -0.07 | -3.89% | 1.80 | 1.85 | 1.72 |
| Mar 25, 2025 | 1.84 | -0.12 | -6.12% | 1.96 | 1.96 | 1.78 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 3:1
- 5:1
- 10:1
- 20:1
- 20
- 100
- 500
- 1000
- 10000
Zentalis Pharmaceuticals Company profile
About Zentalis Pharmaceuticals Inc
Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. It is developing a pipeline of product candidates with a focus on validated oncology targets. Its lead product candidates, ZN-c5, is an oral selective estrogen receptor degrader. ZN-c5 is in a Phase I/II clinical trial for the treatment of estrogen receptor positive, human epidermal growth factor receptor 2-negative and ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase. ZN-c3 is in a Phase I/II clinical trial for the treatment of advanced solid tumors. Its other products include ZN-d5, a selective inhibitor of B-cell lymphoma 2, in development for the treatment of non-Hodgkin’s lymphoma and acute myelogenous leukemia; and ZN-e4, an irreversible inhibitor of mutant epidermal growth factor receptor, in a Phase I/II clinical trial for the treatment of advanced non-small cell lung cancer.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, Zentalis Pharmaceuticals Inc revenues was not reported. Net loss increased 35% to $158.7M. Higher net loss reflects Research & Development Expense - Balanci increase of 88% to $145.9M (expense), Stock-based Compensation in R&D increase from $7.3M to $20.9M (expense), Selling, General & Administrative Expens increase of 31% to $23.7M (expense).
| Industry: | Bio Therapeutic Drugs |
1359 Broadway, Suite 801
NEW YORK
NEW YORK 10018
US
News
ECB interest-rate forecasts – Projections for the next five years
The European Central Bank (ECB) plays a pivotal role in the economic stability of the eurozone, meaning ECB interest-rate forecasts are key to understanding how financial and economic scenarios might evolve.
14:37, 10 April 2025
BlackRock shareholders: Who owns the most BLK stock?
BlackRock is the leading asset manager in the world – but who are its biggest shareholders? Read on to find out.
13:46, 9 April 2025
Bitcoin price predictions 2025–2050: third-party price target
We examine bitcoin price predictions for 2025 and beyond, with insights from third-party analysts and market experts.
10:28, 9 April 2025
Tesla (TSLA) stock forecast 2025 and beyond: third-party Tesla price target
Where will Tesla’s stock be in five years? Can the EV company keep its crown?
08:19, 9 April 2025
JasmyCoin price predictions 2025-2030: Third-party price target
How might JASMY behave in the future?
16:13, 8 April 2025
Australian interest-rate projections: where will rates be in 5 years?
As one of the most closely watched economic indicators, Australian interest-rate projections offer valuable insight into the future of the country’s economy.
21:37, 7 April 2025
Copper price forecast: third-party price target
What’s next for the copper market? Read on for the latest analysis of the commodity's price and potential outlook.
17:31, 14 March 2025People also watch
Still looking for a broker you can trust?
Join the 720,000+ traders worldwide that chose to trade with Capital.com